Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shares Down 11 Percent; Nasdaq Warning Imminent

NEW YORK, March 28 (GenomeWeb News) - Shares in Transgenomic were down 11.11 percent, or $.07, at $.56 in early-afternoon trading --- a few cents above their 52-week low --- prompting the likelihood that the company may get a delisting warning letter from the Nasdaq exchange on Wednesday.

 

If the stock fails to climb to above $1 by the close of market on Wednesday, it will mark 30 consecutive trading days that the shares have closed below $1. IN this case, Transgenomic will receive a warning letter from the Nasdaq threatening the firm with being delisted from the exchange.

 

Transgenomic's shares last closed above $1 on Feb. 14 when they closed at $1.04.

 

The Nasdaq exchange typically sends its listed companies such letters if their shares close below $1 for 30 consecutive trading days. The warning gives the company 90 days to return its closing share price to above $1. If the company fails to raise the price above $1 within 90 days after receiving the letter, and fails to maintain a closing price above that threshold for 10 trading days, it will be downgraded to the Nasdaq small-capitalization market.

 

A Transgenomic official did not immediately return a telephone call seeking comment.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.